Navigation Links
AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
Date:5/20/2013

D, accounting for nearly 44 percent of new cases in the US.vii The number of people with diabetes continues to rise and as a result, the number of people with kidney failure caused by diabetes is growing.iii  Some experts predict that diabetes might soon account for half the cases of kidney failure.vii

About Atrasentan

Atrasentan is an investigational compound that belongs to a class of drugs known as selective endothelin-A receptor antagonists, which block the effect of endothelin-l (ET-l), a peptide that constricts blood vessels in the kidney to negatively impact kidney functions.  Atrasentan is a highly selective endothelin-A receptor antagonist that was discovered and is being developed internally at AbbVie.

About AbbVie

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. In 2013, AbbVie employs approximately 21,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

i Clinical Study Protocol M11-352. AbbVie. Date Accessed: April 1, 2013.

ii European Renal Association - European Dialysis and Transplantation Association (ERA-EDTA). Oral Presentation 034932, "The Selective Type A Endothelin Antagonist Atrasentan Reduces Residual Albuminuria in Patients with Type 2 Diabetes and Nephropathy." <
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AbbVie Named to S&P 500 Dividend Aristocrat Index
2. AbbVie Issues Inaugural Full-Year Outlook for 2013
3. AbbVie to Present at Barclays Global Health Care Conference
4. Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
5. AbbVie to Host First-Quarter Earnings Conference Call
6. AbbVie Reports First-Quarter 2013 Financial Results
7. AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis
8. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
9. AbbVie to Present at Bank of America Merrill Lynch 2013 Health Care Conference
10. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
11. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015  Zimmer Biomet Holdings, Inc. (NYSE ... announced that it will be participating in the Goldman ... Goldman Sachs offices in London ... Company Founded in 1927 and headquartered in ... leader in musculoskeletal healthcare.  We design, manufacture and market ...
(Date:8/27/2015)... 27, 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... platform company serving the pharmaceutical, biotechnology, and ... development and manufacturing subsidiary Shanghai SynTheAll Pharmaceutical ... from the Japan PMDA for the manufacture ... commercial drug in July. STA is now ...
(Date:8/27/2015)... -- Symbiomix today announced the completion of patient enrollment in ... of SYM-1219, which is a single-dose, oral product candidate ... year Symbiomix announced positive results from the first pivotal ... pivotal trial by the end of 2015, which would ... U.S. Food and Drug Administration (FDA) in mid-2016. ...
Breaking Medicine Technology:WuXi PharmaTech's STA Subsidiary Receives First Approval from Japanese Regulatory Authorities 2Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation 2Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation 3Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation 4
(Date:8/28/2015)... ... August 28, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at ... for swift actions to be taken in order to ease the stress on ... says scientists have yet to understand fully the real cause of global warming and ...
(Date:8/28/2015)... , ... August 28, 2015 , ... Super-Sod launched their ... look and updated navigation. The most notable change is the responsive web design. Website ... smart devices. Customers can easily submit quote requests for sod, sign-up for the monthly ...
(Date:8/28/2015)... ... 2015 , ... Santa Rosa was recently recognized, for the fourth consecutive year, ... the KLAS “2015 Midterm Performance Review: Software & Services”, Santa Rosa achieved the highest ... Healthcare and KLAS are directly related to our company culture.” said Richard Helppie, chairman ...
(Date:8/27/2015)... ... August 28, 2015 , ... ... elementary school students’ academic performance in mathematics, according to researchers at Georgia State ... Finance and Policy in July, analyzed the impact of a four-day school week ...
(Date:8/27/2015)... ... , ... This new webinar educates providers about how can they create a ... visit, their authorizations are in check, and they are current with their payments. ... Genesis Chiropractic Software, growing a practice depends on patient experience and clinician’s relationship with ...
Breaking Medicine News(10 mins):Health News:Wake Up and Smell the Sick Atmosphere Says Yisrayl Hawkins in New Article This Week 2Health News:Santa Rosa Consulting Recognized by Modern Healthcare as One of the Top 100 Best Places to Work and from KLAS Research with the Highest Rating for Go-Live Support 2Health News:Four-Day School Week Can Improve Academic Performance, Study Finds 2Health News:Four-Day School Week Can Improve Academic Performance, Study Finds 3Health News:A New Webinar Teaches Chiropractors How to Use Compliance Alerts to Manage Patient Relationships 2
... largest outbreak of mumps over the past two decades. The ... , is believed to have begun in late 2005 at ... that the outbreak is continuing to spread. ,According to ... Prevention, there have been more than 1,000 cases reported so ...
... desirable one! Infact, obesity is being thought of on the ... high-calorie fast foods and soft drinks that are omnipresent, and ... on child obesity, Dr. Goutham Rao, has risen to the ... A Parent's Guide to a Fit, Trim, and Happy Child.” ...
... at Queen's University and the University of Pennsylvania have ... for drugs like Celebrex and Vioxx, administered for treatment// ... of triggering a heart problem ,Co-author Colin Funk, ... Canada Research Chair in Molecular, Cellular and Physiological Medicine ...
... of the Royal Victorian Eye and Ear Hospital in East ... treated by patching the eye.// Doing so might actually slow ... several studies has found. ,“The abrasions on the ... pointless rendering a patient acutely monocular if there is no ...
... of Florida study has found that elderly people turn to ... they were not spiritually inclined during their earlier days.// The ... Aging, says that talking about God may actually increase the ... relatively healthy older adults and 19 hospice patients in North ...
... Pakistani local newspaper three persons with a history of fever ... Sciences (PIMS). //The patients are currently under observation on suspicion ... to The News, 22-year-old Syed Wali, his 8-year-old sister Haleema ... PIMS following manifestation of symptoms of bird flu. ...
Cached Medicine News:Health News:Mumps Outbreak In The US 2Health News:Mumps Outbreak In The US 3
Very fine, blunt tip....
... The e.cam single-detector system ... with unrestricted access for gurneys ... features a clinically versatile open ... automatic body contouring for SPECT ...
Sharp diamond shaped double blade in stainless steel....
AXIOM Multistar is a ceiling-mounted single plane C-Arm system for universal angiography, diagnostics and intervention...
Medicine Products: